NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading ALNY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity, as ALNY operates in the biotechnology sector with a focus on innovative therapies. The current thesis state is mixed, with strong recent financial performance but concerns about future guidance and sector dynamics.
The market currently prices ALNY at a premium compared to its peers, indicating high expectations for future growth. However, there is a notable expectations gap, suggesting that while the valuation is expensive, it is somewhat justified given the company's recent performance.
Fundamentals are likely to remain strong in the near term, supported by recent earnings beats and management's focus on revenue targets. However, the elevated risk of missing guidance in a high-miss-rate industry could pose challenges.
The thesis hinges on ALNY's ability to meet its revenue guidance and control expenses, as well as the performance of sector bellwethers like VRTX, REGN, and ARGX. Positive momentum in the healthcare sector could support ALNY, while negative trends among peers could create headwinds.
In the next 1 to 3 years, ALNY's performance will depend on its execution and the broader healthcare environment. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. A sharp drop in ALNY's stock may be repricing the thesis. Competition remains a concern as market dynamics shift. However, partnerships and commercial momentum still support revenue growth.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Meeting or exceeding this target is key to achieving the full-year revenue goal.
Confirms:Q2 revenue reported at or above $1.225B.
Disproves:Q2 revenue reported below $1.225B.
Why it matters: Staying within this expense range is key for making money.
Confirms:R&D and SG&A expenses reported at $2.7B or lower.
Disproves:R&D and SG&A expenses reported above $2.8B.
Why it matters: If healthcare sector growth speeds up, it may help Alnylam's performance.
Confirms:Healthcare sector revenue growth moves back toward 10% or higher.
Disproves:Healthcare sector revenue growth is slowing down to below 5%.
Why it matters: Managing these costs is important for making money and reaching growth goals.
Confirms:Management states R&D and SG&A expenses are within $2.7B-$2.8B.
Disproves:Management says costs are more than $2.8B.
Why it matters: Enrollment increase in this study could lead to faster data on nucresiran for ATTR-CM.
Confirms:They announced that enrollment for the TRITON-CM study is done ahead of schedule.
Disproves:There are delays in enrollment for the TRITON-CM study. No updates are available.
Why it matters: Growth in TTR franchise revenues is key for Alnylam's 2026 revenue goals.
Confirms:TTR franchise revenues were over $2.5 billion for 2026.
Disproves:TTR franchise revenues were under $2.5 billion for 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
